title: T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
abstract: T-cell large granular lymphocytic (T-LGL) leukemia is characterized by cytopenia and clonal proliferation of large granular lymphocytes. We identified 26 patients with T-LGL leukemia seen at our institution over a period of 8 years. The majority of the patients were asymptomatic at diagnosis. Nine patients were treated with cyclosporine; one achieved a complete remission, and four had a hematological response. Other treatment modalities included single agent alemtuzumab, alemtuzumab combined with pentostatin, fludarabine, and combination of fludarabine and cyclophosphamide. Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients.
authors.affiliation: Department of Leukemia, Unit 428, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Aribi
authors.forename: Yang
authors.initials: Y
authors.lastname: Huh
authors.forename: Michael
authors.initials: M
authors.lastname: Keating
authors.forename: Susan
authors.initials: S
authors.lastname: O'brien
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
authors.forename: William
authors.initials: W
authors.lastname: Wierda
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology*; D015458:Leukemia, T-Cell / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015649:Pentostatin / Q000627:therapeutic use; D012189:Retrospective Studies; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D015649:Pentostatin; D000074323:Alemtuzumab; D016572:Cyclosporine; D014740:Vidarabine; C024352:fludarabine